Last reviewed · How we verify
Placebo (for K-877)
This is a placebo, meaning it has no active therapeutic effect.
This is a placebo, meaning it has no active therapeutic effect. Used for Control in clinical trials for K-877.
At a glance
| Generic name | Placebo (for K-877) |
|---|---|
| Sponsor | Kowa Research Institute, Inc. |
| Modality | Small molecule |
| Phase | Phase 3 |
Mechanism of action
As a placebo, it does not interact with any biological systems or molecular targets. It is used as a control in clinical trials to compare the efficacy of active treatments.
Approved indications
- Control in clinical trials for K-877
Common side effects
Key clinical trials
- Study to Evaluate the Efficacy and Safety of K-808 (Pemafibrate) in Participants With Primary Biliary Cholangitis (PBC) With Inadequate Response to Ursodeoxycholic Acid (UDCA) and/or Obeticholic Acid (OCA) Treatment. (PHASE2)
- Study to Evaluate the Efficacy and Safety of K-877 in Adult Patients With Fasting High Triglyceride Levels and Normal Renal Function (PHASE3)
- Study to Evaluate the Efficacy and Safety of K-877 in Adult Patients With Fasting High Triglyceride Levels and Mild or Moderate Renal Impairment (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Placebo (for K-877) CI brief — competitive landscape report
- Placebo (for K-877) updates RSS · CI watch RSS
- Kowa Research Institute, Inc. portfolio CI